Trials that use: Risk difference
New to this method? Read the tutorial →
4,772 results
- BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Body Mind Training Project: Complete Statistical AnalysisIndependent statistical analysis of Body Mind Training Project: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01564394).
- BOLTIndependent statistical analysis of A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- BOMPIndependent statistical analysis of Evaluation of a Millimeter Wave Emission Bracelet for Improving Parkinson's Disease Symptoms: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.: Complete Statistical AnalysisIndependent statistical analysis of BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor: Complete Statistical AnalysisIndependent statistical analysis of Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Booster Dose Trial: Complete Statistical AnalysisIndependent statistical analysis of Booster Dose Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05016622).
- Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- BOREASAn independent statistical analysis of the phase 3 BOREAS trial of dupilumab versus placebo in COPD with type 2 inflammation, covering the negative binomial exacerbation analysis, MMRM lung-function and symptom endpoints, logistic…
- BortezomibIndependent statistical analysis of Bortezomib to Treat Significant Complication of HSCT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01929980).
- Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00869323).
- Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00075881).
- Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL): Complete Statistical AnalysisIndependent statistical analysis of Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00440726).
- Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma: primary endpoint results, effect estimate with confidence…
- Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin’s Lymphoma That is Recurrent or Did Not Respond to Previous Therapy: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy: primary endpoint results, effect estimate with…
- Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis:…
- BOSTON-4Independent statistical analysis of A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis After Hematopoietic Transplant (BOSTON-4): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- BOTOX® Economic Spasticity Trial (BEST): Complete Statistical AnalysisIndependent statistical analysis of BOTOX® Economic Spasticity Trial (BEST): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00549783).
- BOTOX® for the Treatment of Platysma Prominence: Complete Statistical AnalysisIndependent statistical analysis of BOTOX® for the Treatment of Platysma Prominence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03915067).
- Botulin-A Toxin Instillations and Overactive Bladder: Complete Statistical AnalysisIndependent statistical analysis of Botulin-A Toxin Instillations and Overactive Bladder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00583219).
- Botulism Toxin Injection as a Treatment for Arthritis of the Basal Thumb Joint: Complete Statistical AnalysisIndependent statistical analysis of Botulism Toxin Injection as a Treatment for Arthritis of the Basal Thumb Joint: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Bovine Carotid Artery Biologic Graft and Expanded Polytetrafluoroethylene for Permanent Hemodialysis Access: Complete Statistical AnalysisIndependent statistical analysis of Bovine Carotid Artery Biologic Graft and Expanded Polytetrafluoroethylene for Permanent Hemodialysis Access: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram: Complete Statistical AnalysisIndependent statistical analysis of Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BRAiN-MIndependent statistical analysis of Bringing Relief to Adolescents Naturally Using Melatonin for Migraine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02344316).
- BrainRadioIndependent statistical analysis of Neural Signatures of Parkinson's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01990313).
- BRANCHIndependent statistical analysis of Bare Metal Bifurcation Stent Clinical Trial in Humans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00607321).
- BRAVOIndependent statistical analysis of Buprenorphine to Improve HIV Care Engagement and Outcomes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01936857).
- Break MBIndependent statistical analysis of A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Breast Cancer Risk Biomarkers in Postmenopausal Women: Complete Statistical AnalysisIndependent statistical analysis of Breast Cancer Risk Biomarkers in Postmenopausal Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01252290).
- BREEZE-AD1Independent statistical analysis of A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- BretuximabIndependent statistical analysis of Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment: Complete Statistical AnalysisIndependent statistical analysis of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer’s Type: Complete Statistical AnalysisIndependent statistical analysis of Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- BridgeIndependent statistical analysis of Maintenance of Platelet Inhibition With Cangrelor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00767507).
- Bridging the Evidence-to-practice Gap: Complete Statistical AnalysisIndependent statistical analysis of Bridging the Evidence-to-practice Gap: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03713515).
- Brief Cognitive Behavioral Therapy for Military Populations: Complete Statistical AnalysisIndependent statistical analysis of Brief Cognitive Behavioral Therapy for Military Populations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02038075).
- Brief Educational Video for Patients Prescribed LTBI Treatment: Complete Statistical AnalysisIndependent statistical analysis of Brief Educational Video for Patients Prescribed LTBI Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05412212).
- Brief Group Psychoeducation for Schizophrenia: Complete Statistical AnalysisIndependent statistical analysis of Brief Group Psychoeducation for Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02911519).
- Brigatinib Before Brain Irradiation Trial (B3i Trial): Complete Statistical AnalysisIndependent statistical analysis of Brigatinib Before Brain Irradiation Trial (B3i Trial): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04634110).
- BRIGHTIndependent statistical analysis of Building a Renewed ImaGe After Head & Neck Cancer Treatment (BRIGHT) 2.0: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- BRIGHT AML1019Independent statistical analysis of A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia: primary endpoint results, effect estimate…
- BRIUS Vs FFA Efficiency: Complete Statistical AnalysisIndependent statistical analysis of BRIUS Vs FFA Efficiency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04347018).
- Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BRPIndependent statistical analysis of IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…